JPMorgan Chase & Co. Has $668,000 Position in FibroGen, Inc. (NASDAQ:FGEN)

JPMorgan Chase & Co. increased its stake in shares of FibroGen, Inc. (NASDAQ:FGEN) by 430.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,673,555 shares of the biopharmaceutical company’s stock after buying an additional 1,358,194 shares during the quarter. JPMorgan Chase & Co. owned about 1.66% of FibroGen worth $668,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Point72 DIFC Ltd grew its position in FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 45,990 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in FibroGen during the second quarter worth approximately $130,000. Sei Investments Co. grew its position in FibroGen by 38.4% during the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 41,442 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of FibroGen in the 2nd quarter valued at $145,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of FibroGen by 3,906.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 280,161 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Stock Performance

FibroGen stock opened at $0.49 on Tuesday. The stock has a market capitalization of $49.18 million, a price-to-earnings ratio of -0.40 and a beta of 0.75. FibroGen, Inc. has a 52-week low of $0.18 and a 52-week high of $2.93. The stock’s 50 day moving average price is $0.47 and its two-hundred day moving average price is $0.48.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.21. The firm had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same quarter in the prior year, the business earned ($0.52) earnings per share. On average, equities research analysts forecast that FibroGen, Inc. will post -0.8 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on FGEN. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th. HC Wainwright raised FibroGen to a “strong-buy” rating in a report on Tuesday, December 17th. Finally, StockNews.com began coverage on FibroGen in a report on Wednesday, January 1st. They issued a “hold” rating on the stock.

FibroGen Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.